Saint Peter's University joins Curemark's clinical trial program for CM-AT autism treatment

Curemark, LLC , a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment.  

Saint Peter's is affiliated with the Drexel University College of Medicine in Philadelphia.  Drexel University College of Medicine began enrolling patients in the CM-AT autism study earlier this year.  Curemark's clinical trial program for CM-AT now encompasses a total of 13 sites nationwide.  

CM-AT, which has received Fast Track status from the FDA, is based on Curemark's research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein.  The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function.  If approved, CM-AT will be one of the first therapies to address the underlying physiology of autism.  

"We are pleased that trial enrollment is proceeding well at Drexel University College of Medicine and that Saint Peter's is also taking part in the clinical research for CM-AT," said Joan Fallon, Curemark founder and CEO.  "We're currently assessing the viability of other possible sites around the country to join the autism study."

For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."